- Business Insider•7 minutes ago
Close to 8% of the Georgian population is living with hepatitis C, an infection that can...
- Barrons.com•33 minutes ago
Yesterday, Gilead Sciences (GILD) reported Phase 2 trial data on its NASH treatment that was good enough to move on to Phase 3 (even if everyone wasn't convinced). RBC's Michael Yee and team consider the ...
- Investor's Business Daily•47 minutes ago
Gilead's NASH drug is "clearly active and promising," but Intercept Pharmaceuticals remains one to two years ahead, RBC says.
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||73.91 x 100|
|Ask||73.92 x 600|
|Day's Range||73.86 - 74.94|
|52wk Range||72.21 - 111.11|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||6.49|
|Avg Vol (3m)||10,609,706|
|Dividend & Yield||1.88 (2.56%)|